Mass Innovation Labs is Now SmartLabs
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: PR Web
CAMBRIDGE, Mass. (PRWEB) January 18, 2019 Boston-based Laboratory as a Service (LaaS) leader, Mass Innovation Labs, has changed its name to SmartLabs in an effort to better express its continued expansion and service offerings for biotech and life sciences companies. "Meeting the challenges of innovation calls for a new kind of lab: one that is more agile and adaptable than ever before. One that doubles-down on the things that matter most, while eliminating those that impede progress. That's why we felt it was time our name reflects the spirit of our transformational lab design and our mission to accelerate our clients' potential," said CEO and co-founder Amrit Chaudhuri.Chaudhuri points to numerous client successes as proof of SmartLabs' ability to accelerate discovery: "Cue Biopharma was founded here and IPOed in less than 30 months, while CRISPR Therapeutics closed on $450M in pharma deals in its first six months with us. In addition, a number of our clients use SmartLabs as a me
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.MarketBeat
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
- Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business HighlightsGlobeNewswire
CUE
Earnings
- 8/8/23 - Beat
CUE
Sec Filings
- 3/28/24 - Form 10-K
- 3/28/24 - Form S-8
- 3/11/24 - Form SC
- CUE's page on the SEC website